 MONT-SAINT-GUIBERT, Belgium, April 22, 2020 GLOBE NEWSWIRE -- Celyad Euronext Brussels and Paris, and Nasdaq: CYAD, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the decision to host its 2020 Ordinary General Meeting remotely on May 5, 2020 and to postpone its Extraordinary General Meeting to June 8, 2020 from May 5, 2020. In view of the current exceptional circumstances linked to the COVID-19 pandemic and in accordance with Royal Decree No. 4 of April 9, 2020, the Board of Directors of Celyad have decided to prohibit the physical presence of shareholders, and instead plan to webcast the Ordinary General Meeting of May 5, 2020 remotely, via an electronic means of communication. 